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Methotrexate (MTX) is an antineoplastic drug, and due to its high toxicity, the therapeutic drug mon-
itoring is strictly conducted in the clinical practice. The chemometric optimization and validation of a
high performance liquid chromatography (HPLC) method using core–shell particles is presented for the
determination of MTX in plasma during therapeutic monitoring. Experimental design and response
surface methodology (RSM) were applied for the optimization of the chromatographic system and the
analyte extraction step. A Poroshell 120 EC-C18 (3.0 mm75 mm, 2.7 μm) column was used to obtain a
fast and efﬁcient separation in a complete run time of 4 min. The optimum conditions for the chroma-
tographic system resulted in a mobile phase consisting of acetic acid/sodium acetate buffer solution
(85.0 mM, pH¼4.00) and 11.2% of acetonitrile at a ﬂow rate of 0.4 mL/min. Selectivity, linearity, accuracy
and precision were demonstrated in a range of 0.10–6.0 mM of MTX. The application of the optimized
method required only 150 mL of patient plasma and a low consumption of solvent to provide rapid re-
sults.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Methotrexate (MTX, 4-amino-N10-methylpteroylglutamic acid)
is a cytotoxic drug used since the 1940s in the therapy of acute
lymphoblastic leukemia (ALL), non-Hodking lymphoma and cere-
bral tumors [1].
The structure analogy between MTX and folic acid (Fig. 1) is the
basis of its mechanism of action. Its antiproliferative action is de-
veloped by the competitive inhibition of dihydrofolate-reductase
(DHFR), an enzyme involved in folic acid metabolism. At high doses,
MTX follows different metabolic pathways of detoxiﬁcation, pro-
ducing two main metabolites, i.e., 7-hydroxy-MTX (7-OH-MTX) and
4-amino-4-deoxy-N10-methylpteroic acid (DAMPA) [2].
Since MTX inhibits a key cellular function, it is an important
cytotoxic compound, especially on actively replicating cells, but
also on other tissues [1–3]. Thus, MTX is one of the very few an-
tineoplastic drugs for which therapeutic drug monitoring (TDM) is
currently conducted in clinical practice, especially in high-dose
protocols.
In order to allow the use of protocols with very high doses ofon and hosting by Elsevier B.V. Th
University.
De Zan).MTX, a strategy called “leucovorin rescue therapy” has been de-
vised. Administration of leucovorin at a scheduled time after the
infusion of high-dose MTX is beneﬁcial to healthy cells, and pro-
tects them from the cytotoxic action of MTX [1].
Several methods have been developed for the determination of
MTX and its metabolites in human ﬂuids. Firstly, bioanalytical
methods using antibodies, such as radioimmunoassay [4,5],
ﬂuorescent polarization immunoassays (FPIA from Abbott) [6] and
the enzyme multiplied immunoassay technique (EMIT from
Behring Diagnostics) [7], have been used. These techniques have
many advantages in simplicity, speed and cost. However, speciﬁ-
city can be compromised because antibodies can present cross-
reactivity, leading to an overestimation of the actual MTX con-
centration. Recently, an electrochemical approach has been pre-
sented for the determination of MTX, which uses a poly (L-lysine)
modiﬁed electrode in the presence of sodium dodecyl benzene
sulfonate. This sensor provided satisfactory results for a wide
linear concentration range, low detection limit, high selectivity
and good stability. Its practical applicability has been proven by
quantifying MTX in medicinal tablets, but it was not applied to
detect the analyte in biological samples [8].
Among the separation methods, high-performance liquid
chromatography (HPLC) using different detection modes, such as
electrochemistry [9,10], ﬂuorescence through pre- or post-column
oxidation [11], UV [12,13] and mass spectrometry [14,15], is widelyis is an open access article under the CC BY-NC-ND license
Fig. 1. Chemical structures of (A) folic acid and (B) methotrexate.
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In the past few years, sub-3 μm core–shell particles columns
for HPLC have been developed. The premise which drove their
development is the reduced diffusion length for analytes inside
the core–shell particles compared to their fully porous counter-
parts. As the thickness of the porous shell decreases, the faster
mass transfer can lead to improved column efﬁciency and shorter
elution time, reducing both total analysis time and organic solvent
consumption [16,17].
Core–shell particles columns for biological samples have been
reported for the determination of 25-hydroxymetabolites of vita-
min D2 and D3 in serum [18], N-(ω)-hydroxy-nor-L-arginine, L-
arginine and N-(ω)-ethyl-L-arginine in rat plasma [19] and boldine
in rat plasma, urine and bile [20].
As for sample preparation, protein precipitation as the ﬁrst step
is highly recommended, as it is simple, fast and inexpensive. An
extraction step can contribute to further clean-up, in which an
organic solvent is employed to back-extract the solvent used for
protein precipitation, leaving a smaller water volume that can be
directly injected into the chromatographic system.
The development of a new analytical method may involve op-
timization approaches, for which experimental design, especially
response surface analysis and Derringer's desirability function, are
valuable tools [21,22].
Response surface methodology (RSM) is a statistical and
mathematical technique used to model the experimental data and
obtain the polynomial equation that best ﬁts the response beha-
vior [23]. When more than two responses are to be optimized
simultaneously, the Derringer's desirability function is a useful
strategy for ﬁnding the operative conditions that satisfy the opti-
mization criteria for all the responses taken into account [24].
Once the method is developed and optimized, a full validation
should be performed. The main characteristics of a bioanalytical
method, which are essential for ensuring the acceptability of the
performance and the reliability of analytical results, are selectivity,
lower limit of quantiﬁcation, response function and calibration
range, accuracy, precision, matrix effects, stability of the analyte
(s) in the biological matrix, and stability of the analyte(s) in the
stock and working solutions [25].
In this study, a fast and efﬁcient high performance liquid
chromatography–ultraviolet (HPLC–UV) method was developed
for the determination of MTX in human plasma applicable to the
TDM. Both sample preparation and chromatographic separation
were optimized and the method was validated according to the
European Medicines Agency (EMA) guideline on bioanalytical
method validation [25].2. Materials and methods
2.1. Apparatus and software
The HPLC analyses were accomplished using an Agilent 1100
Series system, equipped with a quaternary pump, a membrane
degasser, a thermostated column compartment, an autosampler
and a diode array detector (DAD) (Agilent Technologies, Wald-
bronn, Germany). For data acquisition and processing, the Chem-
station version B 0103 was used.
Experimental design, surface response modeling and desirability
function calculations were performed using the Stat–Ease Design–
Expert 8.0.0.
2.2. Chemicals, reagents and samples
Methotrexate sodium (Na2MTX) freeze-dried preparation for
injection was supplied by Microsules (Buenos Aires, Argentina).
Acetonitrile (HPLC grade) was purchased from Aberkon Química
(José León Suarez, Argentina). Glacial acetic acid (analytical grade)
and chloroform (analytical grade) were purchased from
Laboratorios Cicarelli (San Lorenzo, Argentina), while methylene
chloride (analytical grade) and sodium acetate (analytical grade)
were supplied by Anedra (Buenos Aires, Argentina). Puriﬁed HPLC
grade water was obtained from a Milli-Qs system (Millipore,
Milford, MA, USA).
Real unknown samples containing MTX were obtained from
the remaining volume of plasma used in the laboratory for the
TDM in patients hospitalized at “J.M. Iturraspe Hospital” in city of
Santa Fe (Argentina). These samples were conserved at 4 °C for
less than 6 h until analysis. Blank human plasmas were obtained
from non-treated unidentiﬁed volunteers.
During the method development, pooled plasma samples pre-
pared by mixing several samples from different hours post infu-
sion were used to obtain an average concentration of MTX and
7-OH-MTX.
2.3. Calibration solutions and quality control (QC) samples
MTX stock standard solution at 1250 µM was prepared by
weighing and dissolving an appropriate amount of Na2MTX in
50.0 mL of puriﬁed water. Calibration solutions were prepared by
adding appropriate volumes of stock standard solution to blank
human plasma. The ﬁnal MTX concentrations in the calibration
solutions were 0.10, 0.50, 1.00, 1.50, 2.00, 4.00, and 6.00 mM.
QC samples were prepared by diluting the stock solution with
blank plasma at 0.10, 0.30, 3.0 and 4.5 mM, to obtain low limit
of quantiﬁcation (QC-LLOQ, 0.10 µM), and low (QC-L, 0.30 µM),
medium (QC-M, 3.0 µM) and high (QC-H, 4.5 µM) concentration
levels, respectively.
2.4. Sample preparation
The procedure used for the extraction of the analyte from
plasma samples consisted of two steps, i.e., protein precipitation
using acetonitrile (ACN) with a ratio of 2:1 (ACN:plasma), and then
the back-extraction of the solvent used for protein precipitation.
For this purpose, chloroform and methylene chloride were
evaluated. The performance of this procedure was optimized by
experimental design and RSM.
2.5. Chromatographic separation
The separation was achieved using a Poroshell 120 EC-C18
(3.0 mm75 mm, 2.7 μm) column (Agilent Technologies) and
monitored at 305 nm. The mobile phase consisted of acetic acid/
Table 2
Full factorial design for extraction optimization.
Run Factors Responses
DPVa ESVb ESTc MTX area EVd
1 200 200 Ce 130.5 40
2 200 400 Ce 127.5 40
3 400 600 Ce 129.5 80
4 200 600 Ce 130.7 40
5 400 400 Ce 128.5 70
6 600 200 Ce 40.1 70
7 400 400 Ce 132.0 80
8 400 200 Ce 55.5 100
9 600 400 Ce 89.8 150
10 400 400 Ce 123.0 100
11 600 600 Ce 128.8 150
12 200 400 MCf 125.6 30
13 200 200 MCf 131.1 40
14 200 600 MCf 133.8 30
15 400 400 MCf 128.6 100
16 400 600 MCf 131.2 100
17 600 400 MCf 135.7 150
18 400 400 MCf 131.1 90
19 400 400 MCf 131.8 60
20 600 200 MCf – 150
21 600 600 MCf 128.8 160
22 400 200 MCf 78.4 70
a Deproteinized plasma volume in mL.
b Extraction solvent volume in mL.
c Extraction solvent type.
d Extract volume in mL.
e Chloroform.
f Methylene chloride.
Table 1
Central composite design for chromatographic separation optimization.
Run Block Factors Responses
SAa pH ACN (%) Temp. (°C) R1 R2 W1 W2 T (min)
1 1 62.5 5.50 16.25 35.0 0.94 1.17 – – 1.01
2 1 87.5 4.00 8.75 25.0 10.89 10.99 0.300 0.330 10.2
3 1 87.5 4.00 16.25 35.0 2.55 2.59 0.078 0.081 1.53
4 1 87.5 5.50 8.75 35.0 6.76 3.03 0.390 0.350 5.40
5 1 75.0 4.75 12.50 30.0 1.92 0.00 – – 1.57
6 1 87.5 5.50 16.25 25.0 2.01 0.00 – – 1.08
7 1 62.5 5.50 8.75 25.0 4.62 1.07 0.530 0.620 4.20
8 1 62.5 4.00 8.75 35.0 3.04 1.39 0.840 1.68 6.17
9 1 62.5 4.00 16.25 25.0 2.95 3.28 0.069 0.077 1.62
10 1 75.0 4.75 12.50 30.0 5.63 5.79 0.120 0.120 3.02
11 2 75.0 4.75 12.50 30.0 3.09 1.68 0.230 0.250 2.34
12 2 62.5 4.00 16.25 35.0 2.48 2.45 0.077 0.084 1.50
13 2 75.0 4.75 12.50 30.0 3.73 2.34 0.190 0.200 2.47
14 2 87.5 5.50 8.75 25.0 6.76 2.35 0.420 0.470 5.41
15 2 87.5 5.50 16.25 35.0 2.03 0.00 – – 1.04
16 2 62.5 4.00 8.75 25.0 11.61 12.33 0.260 0.350 11.5
17 2 62.5 5.50 8.75 35.0 7.92 4.14 0.310 0.260 5.45
18 2 62.5 5.50 16.25 25.0 2.03 0.00 – – 1.04
19 2 87.5 4.00 8.75 35.0 9.83 9.22 0.220 0.240 7.01
20 2 87.5 4.00 16.25 25.0 2.88 3.32 0.067 0.073 1.61
21 3 75.0 4.75 20.00 30.0 1.76 0.00 – – 1.02
22 3 100.0 4.75 12.50 30.0 3.41 1.83 0.190 0.200 2.21
23 3 75.0 4.75 12.50 30.0 3.39 1.73 0.190 0.220 2.19
24 3 75.0 3.25 12.50 30.0 3.34 5.94 0.076 0.076 2.13
25 3 75.0 6.25 12.50 30.0 5.07 8.79 0.087 0.099 3.04
26 3 75.0 4.75 12.50 30.0 2.43 0.66 0.210 0.300 1.72
27 3 50.0 4.75 12.50 30.0 3.34 1.66 0.210 0.240 2.29
28 3 75.0 4.75 12.50 20.0 4.67 2.98 0.160 0.190 2.67
29 3 75.0 4.75 5.00 30.0 19.1 – 0.350 – –
30 3 75.0 4.75 12.50 30.0 4.63 2.61 0.120 0.140 2.17
31 3 75.0 4.75 12.50 40.0 6.16 4.00 0.060 0.064 1.96
a Sodium acetate concentration in mM.
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0.4 mL/min, and the injection volume was 20 mL. The rest of the
chromatographic parameters were optimized by experimental
design and RSM.
2.6. Chromatographic optimization
In the ﬁrst place, the responses to be optimized were selected
in order to reach short analyses time and complete resolution
between MTX and 7-OH-MTX peaks. It is worth noting that
DAMPA was not considered for the optimization as it is a minor
metabolite. A high-concentration solution of DAMPA was injected
into the chromatographic system and several real samples were
analyzed. It was conﬁrmed that the level of DAMPA in plasma after
infusion is undetectable by this method. Therefore, the ﬁve re-
sponses were resolution between MTX peak and the peak corre-
sponding to endogenous plasma components (R1), resolution be-
tween MTX and 7-OH-MTX peaks (R2), complete runtime (T) and
peak width of MTX (W1) and 7-OH-MTX (W2).
The analyzed factors, i.e., buffer concentration and pH, per-
centage of ACN in the mobile phase and oven temperature, were
chosen from the literature as they have more inﬂuence on the
responses under study.
The central composite design (CCD) consisted of 31 experi-
ments, including the combinations of factors at different levels and
seven central points. The ranges studied for the four factors were
50.0–100.0 mM for the buffer concentration, 3.25–6.25 for the
buffer pH, 5.00%–20.00% of ACN in the mobile phase, and 20.0–
40.0 °C for the oven temperature. The order of the experiments
M. Montemurro et al. / Journal of Pharmaceutical Analysis 6 (2016) 103–111106was randomized to minimize systematical error, and the experi-
ments were divided into three blocks (Table 1). A pooled plasma
sample containing both compounds, MTX and 7-OH-MTX, was
employed in the optimization of experiments.
2.7. Extraction optimization
The selected factors for this optimization were volume of
plasma after deproteinization and volume of extraction solvent.
Chloroform and methylene chloride were evaluated for the ex-
traction as categorical factors in the design. The optimized re-
sponses were MTX recovery, and the volume of the extract ob-
tained after the extraction procedure.
A three-level full factorial design (FFD), consisting of 22 ex-
periments, i.e., 11 for chloroform and 11 for methylene chloride,
was built. The studied ranges were 200–600 μL for both factors
(Table 2). A blank plasma sample spiked with MTX in a ﬁnal
concentration of 2.0 mM was employed for the optimization of
experiments.
The experiments were performed in one block, and the order
was randomized to minimize systematical errors.
2.8. Method validation
The method was validated following the EMA guideline on
bioanalytical method validation. The following parameters were
evaluated: selectivity, LLOQ, calibration curve regression model,
accuracy, precision, dilution integrity and stability of the analyte in
the stock solution under the entire period of storage and proces-
sing conditions.3. Results and discussion
3.1. Chromatographic optimization
The responses obtained in the experimental design runs (Ta-
ble 1) were ﬁtted into suitable models obtained by the multiple
regression technique and the least square method, in order to
describe their behavior as a function of the analyzed factors. The
second degree polynomial model used is shown in Eq. (1):
∑ ∑ ∑β β β β ε= + + + +
( )= ≤ ≤ =
y x x x x
1i
k
i i
i j
k
ij i j
i
k
ii i0
1 1 1
2
where y is the response to be optimized, xij are the factors, β0 is
the overall mean effect, βi represents the effect of the factor xi, βij
is the effect of the ij interaction between the factors xi and xj, and εTable 3
Models ﬁtting.
Central composite design
Natural
response
Transformation Transformed
response
Model Signiﬁcant ter
R1 Natural log ′=y Rln 1 Linear C
R2 Square root ′= +y R 0.12331 2FI
c B-C-BD
T Inverse square root ′=y
T
1 Quadratic B-C-C2
W1 – – Quadratic C-D-AD-BC-BD
W2 – – Quadratic C-D-AD-BC-BD
a ANOVA test (α¼0.05): A¼buffer concentration (mM), B¼pH, C¼ACN (%), D¼tem
b ANOVA test (α¼0.05): A¼volume of deproteinized plasma (mL), B¼volume of ext
c 2FI indicates model with linear terms and interaction.is a random error component.
Some of the responses had to be transformed in order to
achieve variance stabilization and normal distribution of residuals.
The Box–Cox graphical strategy was used to ﬁnd the appropriate
transformation function [21]. Table 3 shows the transformations
applied to the responses and the models adjusted by the analysis
of variance (ANOVA) for each one. ANOVA is a statistical test used
to analyze the differences between group means and their asso-
ciated procedures. According to Eq. (1), the appropriate hy-
potheses for model evaluation are
β
β
= = … = =
≠ ( )
H b b
H k
: 0
: 0 for at least one 2
i ij k
k
0
1
ANOVA estimates three variances: a total variance based on all
the observation deviations from the grand mean; an error variance
based on all the observation deviations from their appropriate
treatment means, and a treatment variance. In this case, the
treatment is the factor level. To determine the statistical sig-
niﬁcance of the model, the F-test is used. If the calculated F0 ex-
ceeds Fα,k1,k(n1), the H0 is rejected and there is at least one
variable that contributes signiﬁcantly to the model.
The desirability function was applied later for the simultaneous
optimization of the responses. The optimization criteria (Table 4)
were selected in order to reach short analysis time and good re-
solution between the peaks, and also to obtain symmetrical bands.
The levels for the factors that gave the maximum of the de-
sirability function (D¼0.703) were 85.0 mM and 4.00 for the
buffer concentration and pH, respectively, 11.2% for ACN and 25 °C
for the column oven. The response surface of the global desir-
ability for pH and ACN percentage is shown in Fig. 2. These opti-
mization results were experimentally checked and the experi-
mental responses were compared with those predicted by the
model. Predicted responses and experimental results are shown in
Table 4. The chromatogram obtained at the optimal conditions is
shown in Fig. 3. As can be seen, the peaks are completely resolved
in a total run time of 4 min. In addition, the peaks for both com-
pounds, i.e., MTX and 7-OH-MTX, show acceptable widths.
3.2. Extraction optimization
As it was done for the chromatographic optimization, each of
the responses (Table 2) was ﬁtted into a suitable model and AN-
OVA test was applied for model validations.
The models and signiﬁcant terms are shown in Table 3. The
models suggest that the volume of extract obtained was not in-
ﬂuenced by the volume of extraction solvent employed, but it was
affected by the volume of plasma. On the other hand, no factor wasFull factorial design
msa Response Chloroform Methylene chloride
Model Signiﬁcant
termsa
Model Signiﬁcant
termb
Area Quadratic A-B-AB-B2 – –
Extract
volume
Linear A Linear A
-B2-C2-D2
-B2-D2
p. (°C).
raction solvent (mL).
Table 4
Criteria for the optimization of individual factors and responses.
Optimization Factors Response Goal Prediction Experimental
results
CCD R1 Maximize 6.43 7.40
R2 Maximize 7.19 9.40
T Minimize 5.51 4.70
W1 Minimize 0.058 0.142
W2 Minimize 0.054 0.148
FFD DPVa Minimize – –
ESVb Minimize – –
Chloroform Area Maximize 106.2 121.0
EVc Maximize 80 70
Methylene
chloride
Area Maximize 131.1 78.0
EV Maximize 88 50
CCD: central composite design. FFD: full factorial design.
a Deproteinized plasma volume.
b Extraction solvent volume.
c Extract volume in mL.
Fig. 2. Response surface of the global desirability as a function of pH and ACN. The
other factors are at their optimum.
Fig. 3. Chromatogram of a pooled plasma sample obtained under the optimized
conditions.
Fig. 4. Response surface for MTX area as a function of plasma volume and ex-
traction solvent volume.
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extraction solvent; therefore, no model could be built for this
particular response. In the case of chloroform, the ﬁtted model
was quadratic and the response surface is shown in Fig. 4.
For the optimization of the responses, the desirability function
was applied and the criteria were selected in order to achieve both
higher MTX recovery and extract volume. In addition, the factors
were also included in the global desirability function to minimize
the organic solvent and the plasma volume required for the
analysis.
The levels of the factors that maximized the desirability func-
tion were 350 mL of deproteinized plasma and 300 mL of chloro-
form, or 400 mL of deproteinized plasma and 200 mL of methylene
chloride. The response surface of the global desirability for both
factors and chloroform as extraction solvent is shown in Fig. 5. The
optimization results were experimentally checked and the re-
sponses were compared with those predicted by the model. The
optimization criteria and the results are shown in Table 4.
As can be seen in the experimental results, methylene chloride
gives lower values than those predicted by the model, whereas
chloroform shows better results according to the predictions, and
presents much higher MTX recovery and more extract volume.
Since chloroform achieves the goal of optimization, it was selected
as extraction solvent and the optimized conditions were used.
Considering these results, the optimized extraction procedureconsisted in the addition of 300 mL of ACN to 150 mL of plasma for
protein precipitation. Precipitated proteins were separated by
centrifugation and 350 mL of deproteinized plasma were trans-
ferred to a new eppendorf tube. 300 mL of chloroform was added
for back-extracting ACN. Finally, 50 mL of the aqueous extract was
transferred to a vial for injection.
3.3. Method validation
3.3.1. Selectivity
The study of selectivity was carried out by evaluating four kinds
of interferences, i.e., those produced by the blank matrix, meta-
bolites, hemolysis and co-administrated medication. For the ﬁrst
case, six individual plasma samples from people who were not
treated with MTX were tested. For metabolites and hemolysis
studies, three plasma samples and three whole blood samples
from people under MTX treatment were evaluated. The drugs
selected as the co-administrated medication were folic acid,
leucovorin, dexamethasone, mercaptopurine, ondansetron,
Fig. 5. Response surface of the global desirability as a function of solvent volume
and plasma volume.
M. Montemurro et al. / Journal of Pharmaceutical Analysis 6 (2016) 103–111108vancomycin and vincristine. These drugs are often simultaneously
administered during the treatment with MTX and their inter-
ference needs to be tested.
The presence of any peak overlapped with the peak of MTX was
studied. Except for folic acid, which has an absorption spectrum
similar to that for MTX, the co-administered medication neither
absorbs at the wavelength employed for MTX detection, nor pro-
duces strongly retained peaks, thus they do not interfere. The
chromatographic run for the plasma spiked with folic acid showed
its signal in the front peak, which is away from the retention time
of MTX (Fig. 6).
For the rest of the tests, no peak with retention time similar to
that expected for MTX was found. Therefore, it can be stated that
the method is selective for the analyte under study.
3.3.2. LLOQ
The peak area for 0.05, 0.10 and 0.20 mM of MTX was obtained
and the recovery and coefﬁcient of variation (CV) were calculated
for each one of them. The lowest concentration of MTX that sa-
tisﬁed the EMA speciﬁcations for precision and accuracy wasFig. 6. Chromatograms obtained with the optimized conditions for0.10 mM, for which a CV of 11% and a recovery of 89.6% were ob-
tained. Therefore, this concentration was established as the LLOQ.
3.3.3. Calibration curve performance
The studied range for MTX concentration in plasma was from
0.10 mM to 6.0 mM at seven levels in triplicate, and the linear re-
lationship between the concentration of MTX and the area of the
peak was proven. Two calibration curves in the complete range on
two different days, and a low level calibration curve in the range of
0.10–1.5 mM were performed. The back calculated concentrations
of the calibration standards were within 715% of the nominal
value, meeting the EMA criteria (Table 5).
3.3.4. Accuracy and precision
Accuracy and precision of the method were evaluated using
ﬁve replicates of QC samples at LLOQ (QC-LLOQ), low (QC-L),
middle (QC-M) and high (QC-H) concentration levels. The QC
samples were analyzed against the calibration curve, and the ob-
tained concentrations were compared with the nominal value. The
CV was calculated for the replicates to evaluate precision. Both
accuracy and precision were studied within a single run and be-
tween different runs; each of them was compared to the two ca-
librations previously performed. The results are shown in Table 6.
The obtained mean concentration was within 15% of the
nominal values for the QC samples, except for the LLOQ which was
within 20% of the nominal value. The CV values did not exceed 15%
for the QC samples. These results met the EMA criteria; therefore,
the accuracy and precision were demonstrated for the developed
method.
3.3.5. Dilution integrity
Dilution integrity was demonstrated by spiking the blank ma-
trix with an MTX concentration above the maximum concentra-
tion of the calibration curve and diluting this sample with blank
matrix. For this purpose, a set of plasma samples were prepared
containing 12.5, 25.0 and 62.5 mM of MTX. The dilution control
samples were obtained by diluting 10 mL of these samples in(A) blank plasma and (B) blank plasma spiked with folic acid.
Table 5
Calibration curve performance.
Nominala Predicteda Recovery (%)b Predicteda Recovery (%)c
0.102 0.109 106.9d 0.086 84.3e
0.107 104.9d 0.091 89.2e
0.103 101.0d 0.082 80.4e
0.510 0.503 98.6d 0.583 114.3e
0.497 97.5d 0.540 105.9e
0.482 94.5d 0.538 105.5e
1.021 1.018 99.7d 0.978 95.8e
0.962 94.2d 0.957 93.7e
0.932 91.3d 0.996 97.6e
1.531 1.522 99.4d 1.528 99.8e
1.550 101.2d 1.528 99.8e
1.531 100.0d 1.581 103.3e
2.042 2.021 99.0 2.166 106.1
1.967 96.3 2.043 100.1
1.934 94.7 1.967 96.3
4.083 4.081 100.0 4.287 105.0
3.847 94.2 4.086 100.1
3.736 91.5 4.239 103.8
6.125 6.077 99.2 5.495 89.7
5.941 97.0 6.245 101.9
6.026 98.4 6.424 104.9
a MTX concentration in mM.
b Calibration 1: slope¼49.6; intercept¼0.4.
c Calibration 2: slope¼50.2; intercept¼0.9.
d Low level calibration 1: slope¼52.9; intercept¼2.3.
e Low level calibration 2: slope¼48.9; intercept¼0.75.
Table 6
Accuracy and precision.
QC Nominala Predicteda
Within-run Between-run
QC-LLOQ 0.100 0.109 0.073
0.101 0.081
0.088 0.086
0.099 0.090
0.103 0.082
QC-L 0.299 0.310 0.258
0.254 0.233
0.303 0.271
0.267 0.246
0.303 0.252
QC-M 2.990 3.203 2.727
3.122 2.892
3.185 2.741
3.170 2.787
3.168 2.856
QC-H 4.486 4.736 4.608
4.674 4.514
4.738 4.516
4.700 4.721
4.758 4.707
a MTX concentration in mM.
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of 0.5, 1.0 and 2.5 mM. Five determinations per dilution factor were
made. The obtained mean concentration was within 10% of the
nominal values and the CV values did not exceed 1%.
These results show that when the expected MTX concentration
exceeds the calibration range, a proper dilution can be made to
obtain reliable results that are not affected by the sample
treatment.
3.3.6. Metabolism proﬁles in patients under treatment
Several treatment protocols are currently used for high-dose
MTX therapy including leucovorin administration to prevent the
injury of normal cells. According to one of them, the dosage of
MTX is performed routinely at 24, 42 and 48 h after starting the
drug infusion.
Normograms guiding the duration and degree of rescue with
leucovorin as a function of plasmatic concentration of MTX at
different times after starting the drug administration are being
used in ongoing clinical trials [26].
The levels of MTX as a function of the time after infusion were
studied in different patients with the developed analytical
method.
The pattern of MTX concentration vs. time depends on the
patients, their renal function and their own metabolism. In Fig. 7,
two proﬁles of MTX, especially distinct one from the other, are
shown. Fig. 7A depicts three proﬁles from different patients. At
24 h after infusion, the levels of MTX in plasma were between 50
and 90 mM, decreasing the concentration below 0.25 mM after 48 h
in all of them. Standard leucovorin rescue treatment was applied
in these cases. Fig. 7B shows a completely different situation, in
which the concentration of MTX after 48 h of infusion was
3.90 mM, which is 10 times higher than the value established by
the protocol as acceptable. In this case, not only leucovorin rescue
treatment was sustained, but also the dosage of MTX continuedRecovery (%) CV (%)
Within-run Between-run Within-run Between-run
109.0 73.0 13.4 10.3
101.0 81.0
88.0 86.0
99.0 90.0
103.0 82.0
103.7 86.3 9.6 6.9
84.9 77.9
101.3 90.6
89.3 82.3
101.3 84.3
107.1 91.2 0.94 2.6
104.4 96.7
106.5 91.7
106.0 93.2
109.2 95.5
105.6 102.7 0.72 2.2
104.2 100.6
105.6 100.7
104.8 105.2
106.1 104.9
Fig. 7. Metabolism proﬁles of MTX.
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0.25 mM. This concentration, necessary to end the administration
of leucovorine, was reached only at 168 h after the infusion, when
0.19 mM of MTX in plasma was detected.
The TDM gains importance in these kinds of situations, since
the patient could have been exposed to high levels of MTX for a
long period of time if the monitoring had not been performed,
causing serious damage not only to neoplastic cells but also to
other tissues. Furthermore, it is worth highlighting the importance
of having an accurate method able to detect and quantify low le-
vels of the drugs in a short time and give reliable results that allow
making the proper medical decisions.4. Conclusions
The developed method over this work for the determination of
MTX in plasma by HPLC is fast, selective, accurate and precise, and
allows us to obtain reliable results for the drug concentration in
plasma samples.
The application of experimental design and multiple response
optimization enabled the development of a chromatographic
method with a complete run time of 4 min. In addition, the ex-
traction step allows a simple and high analyte recovery from the
sample, obtaining an aqueous extract free from proteins and lipids
that could damage the chromatographic column. The small vo-
lume of plasma required for the analysis constitutes an additional
advantage, especially when the samples are from pediatric
patients.
The use of core–shell particles, instead of their fully porous
counterparts, was an important additional tool for reducing both
the analysis time and the volume of organic solvents employed
during the runs.
This method was successfully applied to the routine
therapeutic drug monitoring of MTX in patients with ALL, in order
to prevent excessive toxicity. Furthermore, it could be applied to
the TDM of new “targeted therapies” and in the development of
innovative approaches to treatment individualization.Acknowledgments
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